SCHEMBL4472532

SCHEMBL4472532

CN(CCN1CCC(OC(=O)N(c2ccccc2-c2ccccc2)N(C(=O)O)c2ccccc2-c2ccccc2)CC1)C(=O)c1cccc(C(=O)NCCNCc2cccs2)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.41
CHRM3 P20309 7/20 0.38
ADRB2 P07550 3/20 0.38
POLB P06746 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HTR7 P34969 3/20 0.37
SLC5A7 Q9GZV3 1/20 0.36
HTR1A P08908 1/20 0.36
DRD2 P14416 2/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
SMYD2 Q9NRG4 1/20 0.34
DRD4 P21917 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4472533 0.93 CHRM2 (0.43) CHRM2CHRM3ADRB2POLBMEN1
SCHEMBL4490830 0.90 CHRM2 (0.44) CHRM2CHRM3ADRB2HTR7SLC5A7
SCHEMBL4475841 0.89 CHRM2 (0.43) CHRM2CHRM3ADRB2HTR7SLC5A7
SCHEMBL4474955 0.89 CHRM2 (0.40) CHRM2CHRM3ADRB2HTR7SLC5A7
SCHEMBL4491995 0.89 CHRM2 (0.41) CHRM2CHRM3ADRB2HTR7SLC5A7
SCHEMBL4483079 0.89 CHRM3 (0.44) CHRM2CHRM3ADRB2HTR7SLC5A7
SCHEMBL4479676 0.88 CARM1 (0.45) CHRM2CHRM3ADRB2HTR7SLC5A7
SCHEMBL4493960 0.88 CHRM2 (0.42) CHRM2CHRM3ADRB2MEN1KMT2A
SCHEMBL4494191 0.88 CHRM2 (0.43) CHRM2CHRM3ADRB2MEN1KMT2A
SCHEMBL4493963 0.88 CHRM3 (0.45) CHRM2CHRM3ADRB2SLC5A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed